CERo Therapeutics Holdings Net Income
| CERO Stock | 0.04 0 6.25% |
As of the 11th of February 2026, CERo Therapeutics shows the mean deviation of 7.79, and Risk Adjusted Performance of (0.04). CERo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
CERo Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CERo Therapeutics' valuation are provided below:We have found one hundred ten available fundamental signals for CERo Therapeutics Holdings, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate CERo Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself for few more years. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -8.4 M | -8.8 M | |
| Net Loss | -9.6 M | -10 M | |
| Net Loss | (57.61) | (60.49) | |
| Net Income Per E B T | 1.15 | 1.09 |
CERo | Net Income | Build AI portfolio with CERo Stock |
Evaluating CERo Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into CERo Therapeutics Holdings's fundamental strength.
Latest CERo Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of CERo Therapeutics Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CERo Therapeutics financial statement analysis. It represents the amount of money remaining after all of CERo Therapeutics Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CERo Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.3 M) | 10 Years Trend |
|
Net Income |
| Timeline |
CERo Net Income Regression Statistics
| Arithmetic Mean | (1,515,206) | |
| Coefficient Of Variation | (176.57) | |
| Mean Deviation | 1,971,299 | |
| Median | (315,547) | |
| Standard Deviation | 2,675,391 | |
| Sample Variance | 7.2T | |
| Range | 7.7M | |
| R-Value | (0.65) | |
| Mean Square Error | 4.4T | |
| R-Squared | 0.43 | |
| Significance | 0 | |
| Slope | (346,097) | |
| Total Sum of Squares | 114.5T |
CERo Net Income History
Other Fundumenentals of CERo Therapeutics
CERo Therapeutics Net Income component correlations
CERo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CERo Therapeutics is extremely important. It helps to project a fair market value of CERo Stock properly, considering its historical fundamentals such as Net Income. Since CERo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CERo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CERo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could CERo diversify its offerings? Factors like these will boost the valuation of CERo Therapeutics. Projected growth potential of CERo fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CERo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding CERo Therapeutics requires distinguishing between market price and book value, where the latter reflects CERo's accounting equity. The concept of intrinsic value - what CERo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CERo Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between CERo Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CERo Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CERo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
CERo Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CERo Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CERo Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in CERo Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding CERo Therapeutics Holdings or generate 0.0% return on investment in CERo Therapeutics over 90 days. CERo Therapeutics is related to or competes with Liminatus Pharma, XORTX Therapeutics, Galmed Pharmaceuticals, Biovie, Elevai Labs, BriaCell Therapeutics, and Moolec Science. CERo Therapeutics is entity of United States More
CERo Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CERo Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CERo Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 49.8 | |||
| Value At Risk | (17.27) | |||
| Potential Upside | 20.0 |
CERo Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CERo Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CERo Therapeutics' standard deviation. In reality, there are many statistical measures that can use CERo Therapeutics historical prices to predict the future CERo Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.77) | |||
| Treynor Ratio | (0.74) |
CERo Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.73) | |||
| Mean Deviation | 7.79 | |||
| Coefficient Of Variation | (1,574) | |||
| Standard Deviation | 10.54 | |||
| Variance | 111.13 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.77) | |||
| Treynor Ratio | (0.74) | |||
| Maximum Drawdown | 49.8 | |||
| Value At Risk | (17.27) | |||
| Potential Upside | 20.0 | |||
| Skewness | 0.7032 | |||
| Kurtosis | 0.7225 |
CERo Therapeutics Backtested Returns
CERo Therapeutics secures Sharpe Ratio (or Efficiency) of -0.084, which signifies that the company had a -0.084 % return per unit of risk over the last 3 months. CERo Therapeutics Holdings exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CERo Therapeutics' risk adjusted performance of (0.04), and Mean Deviation of 7.79 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.91, which signifies possible diversification benefits within a given portfolio. CERo Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, CERo Therapeutics is expected to follow. At this point, CERo Therapeutics has a negative expected return of -0.83%. Please make sure to confirm CERo Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if CERo Therapeutics performance from the past will be repeated in the future.
Auto-correlation | -0.15 |
Insignificant reverse predictability
CERo Therapeutics Holdings has insignificant reverse predictability. Overlapping area represents the amount of predictability between CERo Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CERo Therapeutics price movement. The serial correlation of -0.15 indicates that less than 15.0% of current CERo Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.15 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CERo Therapeutics Holdings reported net income of (8.3 Million). This is 102.43% lower than that of the Biotechnology sector and 111.86% lower than that of the Health Care industry. The net income for all United States stocks is 101.45% higher than that of the company.
CERo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CERo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics of similar companies.CERo Therapeutics is currently under evaluation in net income category among its peers.
CERo Fundamentals
| Return On Asset | -2.1 | ||||
| Current Valuation | 8.56 M | ||||
| Shares Outstanding | 21.1 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 1.03 % | ||||
| Number Of Shares Shorted | 192.89 K | ||||
| Gross Profit | (500 K) | ||||
| EBITDA | (6.57 M) | ||||
| Net Income | (8.3 M) | ||||
| Total Debt | 1.58 M | ||||
| Book Value Per Share | (8.85) X | ||||
| Cash Flow From Operations | (5.79 M) | ||||
| Short Ratio | 0.83 X | ||||
| Earnings Per Share | (3.01) X | ||||
| Target Price | 30.0 | ||||
| Beta | 0.3 | ||||
| Market Capitalization | 949.62 K | ||||
| Total Asset | 6.21 M | ||||
| Retained Earnings | (70.92 M) | ||||
| Working Capital | (3.69 M) | ||||
| Net Asset | 6.21 M |
About CERo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CERo Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with CERo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with CERo Stock
Moving against CERo Stock
| 0.62 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.59 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.55 | DSGN | Design Therapeutics | PairCorr |
| 0.52 | ENGN | enGene Holdings Common | PairCorr |
| 0.35 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Biotechnology sector continue expanding? Could CERo diversify its offerings? Factors like these will boost the valuation of CERo Therapeutics. Projected growth potential of CERo fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CERo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding CERo Therapeutics requires distinguishing between market price and book value, where the latter reflects CERo's accounting equity. The concept of intrinsic value - what CERo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CERo Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between CERo Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CERo Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CERo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.